Finance

Cancer biotech Arcellx files for a $100 million IPO – Renaissance Capital

Cancer biotech Arcellx files for a $100 million IPO. January 14, 2022. ACLX. Arcellx, a Phase 1 biotech developing immunotherapies for patients …

Read more @ www.renaissancecapital.com

Back to top button